Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

ADVM holding history

Adverum Biotechnologies, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

ADVM overviewAll 13F holders of ADVMFull Q2 2026 holdings

Shares (Q4 2025)
0
Sold out in Q4 2025
Value
$0
% of portfolio
0.0%
Quarters held
19
Since Q1 2021
Holdings of ADVM by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q4 20250$00.0%−5,585−100.0%Sold outHolders
Q3 20255,585$25.3K<0.1%−8,585−60.6%ReducedHolders
Q2 202514,170$30.5K<0.1%−43,378−75.4%ReducedHolders
Q1 202557,548$251.5K<0.1%+9,952+20.9%AddedHolders
Q4 202447,596$222.3K<0.1%+35,188+283.6%AddedHolders
Q3 202412,408$87.1K<0.1%+6,050+95.2%AddedHolders
Q2 20246,358$43.6K<0.1%+5,426+582.2%AddedHolders
Q1 2024932$13.2K<0.1%+851+1,043.6%AddedConverted for a 1-for-10 splitHolders
Q4 2023815$614<0.1%+15+1.9%AddedHolders
Q3 2023800$1.20K<0.1%−5,490−87.3%ReducedHolders
Q2 20236,290$10.0K<0.1%−8,689−58.0%ReducedHolders
Q1 202314,979$10.7K<0.1%+14,179+1,772.4%AddedHolders
Q4 2022800$464<0.1%00.0%UnchangedHolders
Q3 2022800$1.00K<0.1%00.0%UnchangedHolders
Q2 2022800$1.00K<0.1%−250−23.8%ReducedHolders
Q1 20221,050$1.00K<0.1%−2,131,591−100.0%ReducedHolders
Q4 20212,132,641$3.75M<0.1%−1,011,028−32.2%ReducedHolders
Q3 20213,143,669$6.82M<0.1%+22,343+0.7%AddedHolders
Q2 20213,121,326$10.9M<0.1%−175,063−5.3%ReducedHolders
Q1 20213,296,389$32.5M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.